

Esbriet (pirfinidone) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:		
			additional documentation that is	
•	. •	o support the authorization r	request). Information contained in	
this form is Protected Hea	alth Information under HIPAA.			
			☐ URGENT	
MEMBER INFORMATIO	N _			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:	
STREET ADDRESS:				
CITY:		STATE: ZIP CO	STATE: ZIP CODE:	
PATIENT INSURANCE ID	NUMBER:			
	HEIGHT (IN/CM): WE	EIGHT (LB/KG): ALL	.ERGIES:	
IF YOU ARE NOT THE PATIENT OR THE P	PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI D	DISCLOSURE AUTHORIZATION FORM WITH TH	HIS REQUEST WHICH CAN BE FOUND AT THE	
	NRX.COM/MEMBER/EXTERNAL/COMMERCIAL/			
DATIENT'S ALITHODIZED	REPRESENTATIVE (IF APPLICAB	ı c \.		
	TATIVE'S PHONE NUMBER:			
AUTHORIZED REFREGER	TATIVE STITIONE NOMBER.			
PRESCRIBER INFORMAT	TION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY	:	EMAIL ADDRESS:	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:		_		
CITY:		STATE: ZIP CO	STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSO	ON:	
MEDICATION OR MEDI	ICAL DISPENSING INFORMATION	ON		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:	
-		THERAPY/REFILLS:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THE	RAPY INITIATED:	
DURATION OF THERAPY	/ (SDECIEIC DATES).			



Revision Date: 6/1/2023

CAT0078







Esbriet (pirfinidone) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? MEDICATION/THERAPY (SPECIFY DURATION OF THERAPY (SPECIFY DATES): 1. LIST DIAGNOSES: 1. ICD-10: 1. Idiopathic pulmonary fibrosis 1. Other diagnosis: 1. ICD-10 Code(s): 2. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT PRIOR AUTHORIZATION. Clinical Information: Will Esbriet (pirfenidone) be used concurrently with Ofev (nintedanib) therapy? Yes No Is high resolution CT of the chest consistent with a diagnosis of idiopathic pulmonary fibrosis? Yes No (Planum imaging report.) Does the patient have a forced vital capacity (FVC) of 50-90% predicted?* Yes No
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): DURATION OF THERAPY (SPECIFY DATES): RESPONSE/REASON FOR FAILURE/ALLERGY: LIST DIAGNOSES: ICD-10: Idiopathic pulmonary fibrosis Other diagnosis: ICD-10 Code(s): RESPONSE/REASON FOR FAILURE/ALLERGY: ICD-10: 3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT PRIOR AUTHORIZATION. Clinical Information: Will Esbriet (pirfenidone) be used concurrently with Ofev (nintedanib) therapy? Yes No Is high resolution CT of the chest consistent with a diagnosis of idiopathic pulmonary fibrosis? Yes No (Pisubmit imaging report.)
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): DURATION OF THERAPY (SPECIFY DATES): RESPONSE/REASON FOR FAILURE/ALLERGY: LIST DIAGNOSES: ICD-10: Idiopathic pulmonary fibrosis Other diagnosis: ICD-10 Code(s): RESPONSE/REASON FOR FAILURE/ALLERGY: ICD-10: 3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT PRIOR AUTHORIZATION. Clinical Information: Will Esbriet (pirfenidone) be used concurrently with Ofev (nintedanib) therapy? Yes No Is high resolution CT of the chest consistent with a diagnosis of idiopathic pulmonary fibrosis? Yes No (Plane) imaging report.)
□ Idiopathic pulmonary fibrosis □ Other diagnosis: ICD-10 Code(s): 3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT PRIOR AUTHORIZATION. Clinical Information: Will Esbriet (pirfenidone) be used concurrently with Ofev (nintedanib) therapy? □ Yes □ No Is high resolution CT of the chest consistent with a diagnosis of idiopathic pulmonary fibrosis? □ Yes □ No (Plasubmit imaging report.)
□ Idiopathic pulmonary fibrosis □ Other diagnosis: ICD-10 Code(s): 3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT PRIOR AUTHORIZATION. Clinical Information: Will Esbriet (pirfenidone) be used concurrently with Ofev (nintedanib) therapy? □ Yes □ No Is high resolution CT of the chest consistent with a diagnosis of idiopathic pulmonary fibrosis? □ Yes □ No (Plasubmit imaging report.)
PRIOR AUTHORIZATION. Clinical Information: Will Esbriet (pirfenidone) be used concurrently with Ofev (nintedanib) therapy? □ Yes □ No Is high resolution CT of the chest consistent with a diagnosis of idiopathic pulmonary fibrosis? □ Yes □ No (Pl submit imaging report.)
Will Esbriet (pirfenidone) be used concurrently with Ofev (nintedanib) therapy? ☐ Yes ☐ No Is high resolution CT of the chest consistent with a diagnosis of idiopathic pulmonary fibrosis? ☐ Yes ☐ No (Pisubmit imaging report.)
Is high resolution CT of the chest consistent with a diagnosis of idiopathic pulmonary fibrosis? No (Planta is submit imaging report.)
submit imaging report.)
Does the patient have a forced vital capacity (FVC) of 50-90% predicted?* ☐ Yes ☐ No
Is the patient's carbon monoxide (CO) diffusing capacity 30-90% predicted?* ☐ Yes ☐ No
Does the patient have a forced expiratory volume in 1 second/forced vital capacity (FEV1:FVC) ratio ≥ 0.80?* □ Yes □ No
*Please provide supporting documentation including a pulmonary function test (PFT) report and/or other chart notes.
Has the patient tried the generic pirfenidone product? $\ \square$ Yes $\ \square$ No
Does patient have an absolute contraindication to the generic pirfenidone? Yes No *Please provide suppo chart notes.
If the patient has tried the authorized generic pirfenidone and will not be continuing it, has a U.S. FDA MedW Voluntary Reporting Form for adverse drug reactions (FDA Form 3500) been filed with the FDA?
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other informatio physician feels is important to this review?

 $\hbox{@ 2017-2023}$ by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 6/1/2023

CAT0078







MEMBER'S LAST NAME: ______

and arrange for the return or destruction of these documents.

Esbriet (pirfinidone) Prior Authorization Request Form



MEMBER'S FIRST NAME: _____

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Please note: Not all drugs/diagnosis are covered on all plans. This request may I	pe denied unless all required			
information is received.				
ATTESTATION: I attest the information provided is true and accurate to the bes	t of my knowledge. I understand that			
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical				
information necessary to verify the accuracy of the information reported on this	form.			
Prescriber Signature or Electronic I.D. Verification:	Date:			
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If				
you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents				
of these documents is strictly prohibited. If you have received this information in error, please no	otify the sender immediately (via return FAX)			

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

